Stem cell applications in diabetic charcot foot and ankle reconstructive surgery 

Area of Science:

• Orthopedics
• Regenerative Medicine
• Biomaterials

Background:

• Mesenchymal stem cells (MSCs) possess osteogenic potential, differentiating into osteoblasts for bone regeneration.
• Achieving osteoinductive, osteoconductive, and osteogenic properties is crucial for bone repair, especially in challenging surgical cases.
• Diabetic Charcot foot neuroarthropathy presents significant challenges due to poor bone quality and patient comorbidities.

Purpose of the Study:

• To review the efficacy of mesenchymal stem cells (MSCs) in bone regeneration for diabetic Charcot foot patients undergoing reconstructive surgery.
• To compare radiographic healing times and outcomes between patients treated with and without MSC grafting.

Main Methods:

• Review of diabetic Charcot patients who underwent reconstructive surgery.
• Comparison of radiographic healing time between groups with and without MSC grafting.
• Assessment of union rates (non-union, mal-union, delayed union) in both groups.

Main Results:

• Radiographic healing time was significantly shorter in the MSC grafting group (6.4 weeks) compared to the control group (9.2 weeks) (P < 0.024).
• Both groups exhibited instances of non-unions, mal-unions, and/or delayed unions, indicating persistent challenges in bone healing.
• Surgical application of MSCs was found to be safe, with potential efficacy as an autograft substitute, though results remain inconclusive.

Conclusions:

• Mesenchymal stem cells (MSCs) demonstrate potential safety and efficacy in bone regeneration for complex orthopedic cases like diabetic Charcot foot.
• While MSCs may offer benefits, they do not yet conclusively replace autografts as the gold standard in bone reconstruction.
• Further research is needed to fully establish MSCs as a reliable alternative to autografts in challenging limb salvage situations.